Bethesda, Md—The Vaccines and Related Biological Products Advisory Committee to the US Food and Drug Administration has made a final decision on the three antigenic constituents of next year's influenza vaccine.
It unanimously recommended, in the absence of any compelling reason for change, retaining in the vaccine for use this fall the H3N2 component represented by A/Sydney/05/97. Earlier, the committee had recommended retaining in the vaccine the H1N1 component of influenza A, known as A/Beijing/262/95 (JAMA. 1999;281:887-888).
Marwick C. Influenza Vaccine for 1999 Use Is Decided. JAMA. 1999;281(14):1261. doi:10.1001/jama.281.14.1261-JMN0414-4-1